Orphanet Journal of Rare Diseases | Pathogenic Mechanisms of ATP1A3 Mutation-Related Alternating Hemiplegia of Childhood and Bipolar Disorder, and the Therapeutic Potential of Lithium

Recommend:

This study reveals a shared pathogenic mechanism of sodium pump dysfunction in alternating hemiplegia of childhood and bipolar disorder, and proposes lithium as a potential therapeutic strategy, holding significant translational medical value.

 

Literature Overview

The article titled 'Parallels between bipolar disorder and ATP1A3-related diseases: a window into the investigation of lithium for alternating hemiplegia of childhood,' published in the Orphanet Journal of Rare Diseases, reviews and summarizes the significant similarities between Alternating Hemiplegia of Childhood (AHC) and bipolar disorder in clinical manifestations, pathophysiological mechanisms, and treatment responses. The article focuses on the central role of ATP1A3 gene mutations causing sodium pump dysfunction in both diseases and, based on existing evidence, proposes lithium as a potential treatment for AHC. The authors systematically compare neuropsychiatric symptoms, intracellular ion imbalances, animal model responses, and interventions in both diseases, emphasizing the importance of cross-disease mechanistic research for developing therapeutic strategies for rare diseases.

Background Knowledge

Alternating Hemiplegia of Childhood (AHC) is a rare inherited neurodevelopmental disorder primarily caused by mutations in the ATP1A3 gene, which encodes the α3 subunit of the Na⁺/K⁺-ATPase pump. This pump plays a critical role in maintaining neuronal membrane potential and intracellular ion homeostasis. Clinical features of AHC include episodic hemiplegia, dystonia, epilepsy, behavioral abnormalities, and cognitive impairments, with symptoms often triggered by environmental stimuli or stress. Current treatment is mainly based on flunarizine, but with limited efficacy. Bipolar disorder is a severe psychiatric condition characterized by alternating manic and depressive episodes, with pathophysiological mechanisms involving decreased Na⁺/K⁺-ATPase activity and elevated intracellular sodium and calcium levels during mood fluctuations. Notably, lithium is a first-line treatment for bipolar disorder, stabilizing mood by modulating sodium transport and multiple signaling pathways. The ATP1A3-related disease spectrum includes AHC and Rapid-onset Dystonia-Parkinsonism (RDP), both exhibiting neuronal hyperexcitability. Animal models, such as the Myshkin mouse carrying the I810N mutation, not only recapitulate AHC phenotypes but also exhibit mania-like behaviors and respond to lithium and valproate. Despite limited treatment options for AHC, the mechanistic overlap with bipolar disorder suggests that psychiatric treatment strategies could be leveraged. This study, based on the similarity in pathogenic mechanisms, proposes lithium as a potential new therapeutic direction for AHC, addressing an unmet clinical need.

 

Can be used to preliminarily predict phenotypes potentially caused by gene knockout before designing experiments.

Learn More

 

Research Methods and Experiments

This study employs a scoping review approach to systematically compare the similarities and differences between Alternating Hemiplegia of Childhood (AHC) and bipolar disorder in clinical features, pathophysiological mechanisms, animal models, and treatment responses. The authors retrieved relevant literature from multiple databases on ATP1A3 gene mutations, sodium pump dysfunction, lithium’s mechanism of action, and treatments for both conditions. Key aspects analyzed include the clinical manifestations and genotype-phenotype correlations of AHC, the development and phenotypic characteristics of animal models (e.g., Mashlool, Myshkin, and Matoub mice), and the efficacy of existing treatments (e.g., flunarizine, ketogenic diet, topiramate). Simultaneously, the pathophysiology of bipolar disorder was reviewed, particularly the relationship between reduced Na⁺/K⁺-ATPase activity and intracellular sodium accumulation, as well as lithium’s role in regulating ion homeostasis and signaling pathways. By comparing shared pathways—such as aberrant activation of Src kinase and MAPK/ERK pathways—and responses to calcium channel blockers and ketogenic diets, the authors constructed a theoretical framework supporting the potential efficacy of lithium in AHC.

Key Conclusions and Insights

• Alternating Hemiplegia of Childhood (AHC) and bipolar disorder are both closely associated with Na⁺/K⁺-ATPase dysfunction and elevated intracellular sodium levels
• Both disorders exhibit episodic neuropsychiatric symptoms triggered by environmental factors or stress
• Animal models of AHC and bipolar disorder show behavioral improvement in response to lithium and valproate
• Calcium channel blockers (e.g., flunarizine) and ketogenic diets demonstrate therapeutic effects in both conditions
• Although AHC involves a genetic, persistent Na⁺/K⁺-ATPase dysfunction while bipolar disorder involves episodic functional impairments, their downstream signaling pathways overlap
• Lithium may benefit AHC patients by directly reducing intracellular sodium concentrations and correcting ion imbalances caused by Na⁺/K⁺-ATPase dysfunction
• Given the limited treatment options and poor response in most AHC patients, conducting clinical trials with lithium holds significant clinical importance

Research Significance and Outlook

This study provides a novel perspective on treating Alternating Hemiplegia of Childhood by leveraging treatment experience from bipolar disorder to explore lithium’s application in AHC. Although lithium is widely used in psychiatry, research on its effects in ATP1A3-related diseases remains unexplored. This article systematically outlines the alignment between lithium’s mechanism of action and the pathophysiology of AHC, providing a theoretical basis for future clinical trials. Further studies should evaluate the safety and efficacy of lithium in AHC patients, particularly its impact on behavioral abnormalities, seizure frequency, and cognitive function. Additionally, potential interactions between cardiac abnormalities in AHC patients (e.g., shortened QTc) and lithium use should be monitored, with individualized dosing strategies developed. Moreover, other drugs targeting the Na⁺/K⁺-ATPase pump or ion homeostasis should be explored to expand therapeutic options.

 

Assesses the pathogenic potential of gene variants, providing a reference for analyzing variant functionality.

Learn More

 

Conclusion

This article systematically elaborates on the profound similarities in the pathophysiological mechanisms of Alternating Hemiplegia of Childhood (AHC) and bipolar disorder, particularly their shared involvement in Na⁺/K⁺-ATPase dysfunction and intracellular sodium accumulation. This common molecular basis not only explains the overlapping clinical features—such as episodic neuropsychiatric symptoms, sensitivity to environmental stress, and responses to calcium channel blockers and ketogenic diets—but also provides a scientific rationale for cross-application of treatment strategies. Although AHC is a rare genetic disorder and bipolar disorder a common psychiatric condition, animal studies show that lithium effectively improves abnormal behaviors associated with ATP1A3 mutations. Therefore, the authors propose that, despite lithium not yet being tested in AHC patients, its well-established ion-regulating mechanisms strongly support initiating clinical trials. This could not only fill a critical gap in AHC treatment but also offer new intervention strategies for other ATP1A3-related disorders. In summary, this study underscores the importance of cross-disease mechanistic research in advancing treatments for rare diseases, advocating for the repurposing of existing therapies to accelerate translational medicine.

 

Jacqueline Alves Leite, Leandro Augusto de Oliveira Barbosa, Regina L Woods, and Rif S El-Mallakh. Parallels between bipolar disorder and ATP1A3-related diseases: a window into the investigation of lithium for alternating hemiplegia of childhood. Orphanet Journal of Rare Diseases.